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Abstract Mutations in TP53 lead to a defective G1
checkpoint and the dependence on checkpoint kinase 1
(Chk1) for G2 or S phase arrest in response to DNA
damage. In preclinical studies, Chk1 inhibition resulted in
enhanced cytotoxicity of several chemotherapeutic agents.
The high frequency of TP53 mutations in triple negative
breast cancer (TNBC: negative for estrogen receptor, pro-
gesterone receptor, and HER2) make Chk1 an attractive
therapeutic target. UCN-01, a non-selective Chk1 inhibitor,
combined with irinotecan demonstrated activity in advanced
TNBC in our Phase I study. The goal of this trial was to further
evaluate this treatment in women with TNBC. Patients with
metastatic TNBC previously treated with anthracyclines and
taxanes received irinotecan (100–125 mg/m2 IV days 1, 8, 15,
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22) and UCN-01 (70 mg/m2 IV day 2, 35 mg/m2 day 23 and
subsequent doses) every 42-day cycle. Peripheral blood
mononuclear cells (PBMC) and tumor specimens were col-
lected. Twenty five patients were enrolled. The overall
response (complete response (CR) ? partial response (PR))
rate was 4 %. The clinical benefit rate (CR ? PR ? stable
disease C6 months) was 12 %. Since UCN-01 inhibits PDK1,
phosphorylated ribosomal protein S6 (pS6) in PBMC was
assessed. Although reduced 24 h post UCN-01, pS6 levels
rose to baseline by day 8, indicating loss of UCN-01 bio-
availability. Immunostains of cH2AX and pChk1S296 on serial
tumor biopsies from four patients demonstrated an induction of
DNA damage and Chk1 activation following irinotecan.
However, Chk1 inhibition by UCN-01 was not observed in all
tumors. Most tumors were basal-like (69 %), and carried
mutations in TP53 (53 %). Median overall survival in patients
with TP53 mutant tumors was poor compared to wild type (5.5
vs. 20.3 months, p = 0.004). This regimen had limited activity
in TNBC. Inconsistent Chk1 inhibition was likely due to the
pharmacokinetics of UCN-01. TP53 mutations were associated
with a poor prognosis in metastatic TNBC.
Keywords Irinotecan  UCN-01  Chk1  Metastatic triple
negative breast cancer  TP53  p53
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TNBC Triple negative breast cancer






Chk1 Checkpoint kinase 1
ECOG Eastern cooperative oncology group
CTEP Cancer therapy evaluation program
NCI National cancer institute
ANC Absolute neutrophil count
AST Aspartate aminotransferase
ALT Alanine aminotransferase
CTCAE Common terminology criteria for adverse events





TTF Time to treatment failure




CC3 Cleaved caspase 3
Introduction
Approximately 15–20 % of patients with breast cancers are
diagnosed with TNBC, which lacks the expression of
estrogen receptor (ER) and progesterone receptor (PgR)
and gene amplification of HER2 [1]. The median survival
of those with metastatic TNBC is poor, ranging 9–13.3
months in retrospective studies [2, 3]. There is a significant
unmet clinical need to identify new therapeutic targets and
treatment options for this patient population [4].
Cell cycle checkpoints are mechanisms that arrest cell
cycle progression in the presence of DNA damage to prevent
the accumulation of mutations in normal cells but are
exploited by cancer cells as a means of developing resistance
to the cytotoxic effects of DNA damaging agents [5]. The
majority of TNBCs carry mutations in TP53 [6–8], a gene that
encodes the tumor suppressor protein p53 which is required
for G1 checkpoint regulation in the presence of genotoxic
stress [9]. However, cells with deficient p53 rely on check-
point kinase 1 (Chk1) to activate S- and G2-checkpoints for
cell cycle arrest [10–12]. When Chk1 is inhibited, p53-defi-
cient cancer cells undergo ‘‘mitotic catastrophe’’ and apop-
tosis in response to DNA damage [5, 10–12]. Therefore, Chk1
inhibition in combination with DNA damaging agents is a
potential synthetic lethal strategy to kill p53-deficient cells
[13–16]. In addition, Chk1 transcript levels are found to be
significantly elevated in TNBC compared to other breast
cancer subtypes [17, 18], making it a feasible target in TNBC
where TP53 mutations also occur at a high frequency.
UCN-01 (7-hydroxystaurosporine) was the first Chk1
inhibitor introduced in the clinic, although it also inhibits
several other serine-threonine protein kinases, including
certain protein kinase C isoenzymes; Cdk2, 4, and 6; and
PDK1 [13, 19, 20]. Preclinical studies have shown that UCN-
01 abrogates the S- and G2-checkpoints and enhances the
cytotoxic effects of a variety of chemotherapeutic agents
including SN-38, the active metabolite of camptothecin and
irinotecan (a semisynthetic analog of camptothecin) in can-
cer cell lines including those of breast cancer [21–26]. Using
human-in-mouse models of TNBC, we recently demon-
strated that UCN-01 potentiated the cytotoxic effects of iri-
notecan in TP53 deficient human TNBC cells [27]. In our
initial phase I study of UCN-01 and irinotecan in patients
with refractory advanced solid tumor malignancies [28], two
partial responses were observed in women with TNBC. Both
tumors were deficient for p53. Therefore, we hypothesized
that UCN-01 and irinotecan would be an effective regimen in
metastatic TNBC. In this trial, we determined the response
rate, toxicity, and pharmacodynamic effects of irinotecan in
combination with UCN-01 and correlated these findings with
TP53 mutation status, and breast cancer intrinsic subtype, in
women with TNBC [29].
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Patient population and methods
Patients
Eligible patients were at least 18 years of age with histo-
logically confirmed breast cancer, negative for ER and PgR
by immunohistochemistry and HER2 amplification by
FISH and demonstrated an eastern cooperative oncology
group (ECOG) performance status of 0–2. Patients had
recurrent, measurable disease which was previously treated
with an anthracycline and a taxane either in the adjuvant or
metastatic setting and may have received up to three prior
chemotherapeutic regimens for metastatic disease. Stan-
dard laboratory criteria were met and an oxygen saturation
at least 90 % on room air at rest and after walking for
6 minutes was required. Prior chemotherapy or radiother-
apy must have been completed at least 4 weeks prior to
treatment. Patients with known sensitivity to UCN-01 or
irinotecan, insulin-dependent diabetes mellitus or uncon-
trolled intercurrent illness, known diagnosis of Gilbert’s
disease, or chronic unconjugated hyperbilirubinemia were
excluded. The Cancer Therapy Evaluation Program
(P5582), Division of Cancer Treatment and Diagnosis,
National Cancer Institute (CTEP, NCI) and the institutional
review boards at both Washington University School of
Medicine and the University of Virginia Health System
approved this protocol. All patients provided written
informed consent prior to study entry.
Treatment plan and study design
Patients received irinotecan (Camptosar, Pfizer Inc., New
York, NY) 100 or 125 mg/m2 depending on the UGT1A1
genotype (patients with 7/7 allele were treated with
100 mg/m2, other patients 125 mg/m2), as a 90 min intra-
venous infusion on days 1, 8, 15, and 22 and UCN-01
(Kyowa Hakko Kogyo Co., Shizuoka, Japan and supplied
by CTEP, NCI) as a 3 h continuous intravenous infusion on
days 2 and 23 every 42 days. UCN-01 was administered at
70 mg/m2 day 2 and 35 mg/m2 day 23 and all subsequent
doses. Dose modifications for irinotecan and UCN-01
included dose delays and reductions as previously descri-
bed in the report on the phase I study of this combination
[28]. Toxicities were graded according to common termi-
nology criteria for adverse events (CTCAE) version 4.0.
Antitumor response was evaluated by physical examination
and/or imaging at baseline and following every cycle.
Responses were evaluated by RECIST 1.0 [30].
Pharmacodynamic studies
Western blot analyses of peripheral blood mononuclear
cells (PBMC) were collected at baseline, 24 h post
irinotecan but prior to UCN-01 (day 2), 24 h post UCN-
01 (day 3), and on day 8 prior to the second irinotecan
administration during cycle 1 for western blot analyses
of phosphorylated ribosomal protein S6 (pS6), S6,
pAKTS473, AKT, pGSK3b, and GSK3b. The procedures
of sample processing, western blot, and quantification of
pS6 to S6 ratio were described in detail previously [28].
The primary antibodies for pS6S240/244, S6, pAKTS473,
pGSK3b, and GSK3b were from Cell Signaling Tech-
nology, Inc., Danver, MA; and the primary antibodies for
AKT and actin were from Santa Cruz Biotechnology,
Delaware, CA, and Sigma Chemical Co., St. Louis, MO,
respectively.
Immunofluorescent (IF) staining of tumors
Serial tumor biopsies of chest wall recurrences from
five consented patients (patients 1, 3, 4, 6, and 11) were
obtained at baseline, 24 h post irinotecan but prior to
UCN-01 (day 2), 24 h post UCN-01 treatment (day 3)
for immunofluorescent staining (IF) of pS6, cleaved
caspase 3, phistone H3, pChk1S296, and cH2AX. Tumor
biopsies were fixed in formalin, processed for hema-
toxylin and eosin staining, and reviewed by a patholo-
gist to confirm cellularity prior to IF staining studies.
Sample processing, antibodies and IF staining were
performed as previously described [27]. The primary
antibodies were pS6S240/244 (Cell Signaling Technology,
Inc.), pChk1S296 (Epitomics, Inc., Burlingame, CA),
cleaved caspase 3 (Cell Signaling Technology), phistone
H3S28 (1:1,000, Sigma-Aldrich Co.), and cH2AXS139
(Cell Signaling Technology, Inc.). Tumor cells staining
positive for phistone H3 and/or cH2AX or cleaved
caspase 3 were counted in five randomly selected fields
per tumor at 400X magnification. Between 225 and
1700 tumor cells were counted.
DNA extraction and TP53 sequencing of tumors
Tumor genomic DNA was isolated from 15 patients with
metastatic breast cancer and analyzed for TP53 mutation
by direct nucleotide sequencing of polymerase chain
products of exons 4–9 as described [28].
RNA preparation, RT-PCR, and assignment
of molecular subtyping of tumors
The details on RNA extraction, RT-PCR, and PAM50
Breast Cancer Intrinsic ClassifierTM (PAM50, ARUP
Laboratories, Salt Lake City, Utah) molecular subtyping
assignment were according to previously published meth-
ods [31].
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Statistical considerations
The primary endpoints for the study were the evaluation of
efficacy including the overall response rate defined as
complete response and partial response (CR ? PR), clini-
cal benefit rate [CR ? PR ? SD (stable disease)], time to
treatment failure (TTF), overall survival (OS), and the
evaluation of the side effect profile of this combination.
The study was designed to accrue a minimum of 20
patients to have adequate precision to estimate the true
overall response rate. Precision was defined by the width of
a 95 % exact binomial confidence interval with an expec-
ted observed rate of at least 5/20 or a minimum lower
bound of 8 %.
OS was measured from start of treatment date until date of
death from any cause or last follow, whichever occurred first.
TTF was measured from start of treatment date until date of
treatment discontinuation due to adverse events; physician
discretion; patient withdrawal; progression; death from any
cause; or last follow up, whichever occurred first.
Adverse events were tabulated by severity and fre-
quency of events. Point estimates and 95 % exact binomial
confidence intervals were calculated for all response rates.
The Kaplan–Meier product limit estimator was used to
estimate time to event distributions which included OS and
TTF. The logrank test was used to test for differences in
time to event distributions with a two-sided test.
Graphical methods were used to display pharmacody-
namic measures, and analyses were considered exploratory.
Repeated measure models were used to estimate the pattern




Between January 2007 and November 2010, 25 patients
with metastatic TNBC were enrolled. Patient characteris-
tics are summarized in Table 1. Patients had prior treat-
ment with an anthracycline and a taxane and the median
number of prior regimens was 3 (ranges 1–4).
Toxicity
Twenty of 25 patients completed at least one cycle of treat-
ment (range 1–6). All 25 patients were evaluated for treat-
ment-related adverse events (Table 2). The most common
hematological toxicities were neutropenia and anemia. Only
1 patient developed febrile neutropenia. The most common
non-hematological toxicities were gastrointestinal toxicities
including nausea/vomiting and diarrhea. Two patients
developed colitis while on study (1 due to Clostridium dif-
ficile). Laboratory abnormalities were observed and were
most often associated with gastrointestinal toxicities. Two
treatment-related elevations in AST/ALT were observed.
One patient with baseline grade 1 AST/ALT and liver
metastases developed a grade 2 fever, grade 3 hyperglyce-
mia, and transient grade 3 ALT/AST elevation within 24 h
following cycle 1, day 2 UCN-01 administration. The
patient’s serum levels of ALT/AST decreased to baseline
level (grade 1) within 2 days and she completed the cycle
without further transaminase elevations. The other patient
developed a grade 3 ALT following cycle 1 week 1 and grade
4 ALT/grade 3 AST during cycle 2 week 4. As per protocol,
this patient was removed from study due to grade 4 ALT.
This patient’s transaminase elevations resolved to grade 1
2 weeks after the last treatment. Several patients had toxic-
ities related to UCN-01. Two patients experienced hypoxia
(grade 2 and grade 3, respectively), and five patients expe-
rienced grade 1 or 2 hypotension during the UCN-01 infusion
that responded to intravenous fluid. As per protocol, the
patient with grade 3 hypoxia, associated with grade 2
hypotension, was removed from study. Hyperglycemia
occurred in over half of the patients, with grade 3 or 4 in five
patients.
Efficacy
Among the 25 patients enrolled, only 22 were evaluated for
response as one withdrew consent and two went off study
during cycle 1 due to toxicities, one due to elevated
transaminases and the other as a result of hypoxia during
the UCN-01 infusion (Table 3). No complete responses
were observed. One PR lasting 24 weeks occurred in a
patient (patient 15) with liver and lung metastasis. This
patient was previously treated with neoadjuvant FEC-T (5-
Fluorouracil, epirubicin, cyclophosphamide followed by
Table 1 Patient characteristics
Characteristic No. of patients (n = 25)
Age (years)
Mean (range) 53 (37–78)
Race







Mean no. of regimens (range) 3 (1–4)
ECOG Eastern cooperative oncology group
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docetaxel) at initial diagnosis and, at disease progression,
with capecitabine followed by paclitaxel and bevacizumab.
Tumor from this patient was found to be basal-like, and
carry a TP53 mutation (Table 4). The overall response rate
(CR ? PR) was 1 in 25 [4, 95 % CI (0, 20 %)]. Two
patients had prolonged disease stabilization that lasted for
37 and 28 weeks, respectively. The clinical benefit rate
(CR ? PR ? SD [ 6 months) was 3 in 25 [12, 95 % CI
(3, 31 %)]. The median TTF and OS were 1.7 months,
95 % CI (1.2, 2.6 months) and 11.3 months, 95 % CI (3.8,
19.0 months), respectively, as shown in Fig. 1a, b. The
study did not meet the pre-defined efficacy criteria for
further evaluation.
Pharmacodynamic studies
PBMCs were collected to evaluate the bioavailability of
UCN-01 over time. Since UCN-01 inhibits PDK1, treat-
ment with UCN-01 was expected to reduce levels of pS6,
pAKT, and pGSK3b [32, 33]. The levels of the phos-
phorylated S6, AKT, and GSK3b were decreased 24 h after
Table 2 Incidence of adverse events
Grade of adverse event (n = 25)
1 2 3 4
Blood and lymphatic system disorders
Anemia 5 12 2 2
Febrile neutropenia 1
Neutrophil count decreased 3 6 3 1
Platelet count decreased 4 2
Gastrointestinal disorders
Abdominal pain 7 1 1
Colitis 1 1
Diarrhea 8 4 3
Nausea/vomiting 13 4 3





Alanine aminotransferase increased 4 1 1
Alkaline phosphatase increased 1 3 1
Aspartate aminotransferase
increased
1 2 2 0
Weight loss 6 2
















Table 3 Response summary
a 1 withdrew consent and 2
went off study during cycle 1
due to toxicity
Best Response N (%)
Partial response 1 (4)
Stable disease 8 (32)
2 [ 6 months
5 [ 3 months
8 [ 2 months
Progressive disease 13 (52)
Not evaluablea 3 (12)













1 PD 1.8 2.0 Basal-like L139N
2 PD 1.5 3.8 Basal-like P151S
3 SD 8.6 20.3 HER2-
enriched
W
4 PD 3.7 14.5 Basal-like W
5 PD 1.0 14.7 Basal-like Insertiona
6 PD 1.6 23.9 N/A W
7 SD 6.5 49.5 Basal-like W
8 SD 4.0 10.6 Basal-like N/A
11 SD 2.6 3.2 Luminal B Deletionb




17 PR 6.1 7.3 Basal-like R273C
19 PD 1.3 2.9 Luminal B W
20 PD 1.2 11.3 Basal-like R273C
22 PD 1.2 19.0 HER2-
enriched
W
23 SD 2.8 20.6 Basal-like W
25 PD 1.2 2.3 Basal-like R273H
Bold serial tumor biopsies at baseline, day 2 (24 h after irinotecan)
and day 3 (24 h after UCN-01)
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UCN-01 on day 3, but returned to baseline on day 8 in most
patients (n = 24, data not shown). Representative western
blots pre- and post-therapy are shown for two patients
(Fig. 2a). The ratio of pS6 to S6 was quantified at baseline
(n = 24), day 1 (n = 24), day 3 (n = 22), and day 8
(n = 20) (Fig. 2b). Compared to baseline, the ratio of pS6
to S6 was decreased significantly (p \ 0.001) 24 h after
UCN-01 on day 3, but not significantly different on day 8,
indicating that UCN-01 activity was not present by day 8.
To evaluate the molecular effects of UCN-01, serial
tumor biopsies were collected at three time points includ-
ing baseline, day 2 (24 h post irinotecan), and day 3 (24 h
post UCN-01) in five patients (1, 3, 4, 6, and 11) with chest
wall recurrences. Tumors from patients 1 and 11 were
mutant for TP53, while those from patients 3, 4, and 6 were
wild type for TP53 (Table 4). Tumor biopsies from patient
3 were not submitted for further analysis because there
were no tumor cells in the baseline sample. Immuno-
staining of cH2AX (marker for double strand DNA
breaks), pChk1S296 (marker of Chk1 activation), phistone
H3 (marker for mitosis), cleaved caspase 3 (CC3) (marker
for apoptosis), and pS6 were performed. As expected from
treatment with irinotecan, there was an increase in double
strand DNA breaks (: cH2AX) (Fig. 2c, d) and activation
of Chk1 (: pChk1S296) (Fig. 2c, e) in all tumors on day 2
biopsy (representative staining from patient 11’s tumor).
phistone H3 staining was low at baseline (1–2 %); there-
fore, the anticipated further reduction of phistone H3 due to
cell cycle arrest from irinotecan was difficult to demon-
strate (Fig. 2c, f). Despite the anticipated pharmacody-
namic effects of irinotecan, there was little induction of
apoptosis on day 2 (Fig. 2c, g). Following UCN-01
therapy, pS6 was reduced in all tumors (Fig. 2c, h).
However, loss of Chk1S296 was only observed in tumors
from patients 6 (TP53 WT (wild type)) and 11 (TP53
deletion) (Fig. 2c, e). Tumor from patient 11, which had a
deletion in TP53, demonstrated the most dramatic increase
in apoptosis with close to 10 % of tumor cells stained
positive for cleaved caspase 3 on day 3 (Fig. 2g). The same
tumor demonstrated a slight increase in phistone H3
(Fig 2f) and an increase in cH2AX (Fig. 2d) following
combination therapy, suggesting cell cycle abrogation and
enhanced DNA damage from the addition of UCN-01. The
patient had a best response of stable disease and a TTF of
2.6 months. Interestingly, tumor from patient 6, which was
WT (wild type) for TP53, showed the most dramatic
increase in phistone H3 (Fig. 2f) following UCN-01, sug-
gesting cell cycle abrogation, but this patient had a best
response of PD and a TTF of 1.6 months on study, indi-
cating ineffective therapy.
In summary, data on pChk1S296 indicated an inconsistent
effect of UCN-01 on Chk1, with one (patient 11) of two TP53
mutant tumors demonstrating the anticipated cell cycle
pharmacodynamic effect (loss of pS296) of UCN-01. How-
ever, given that active Chk1 (p296-phosphorylated form) is
targeted for ubiquitin-mediated proteolysis, there may have
been less total Chk1 in this tumor sample [34–36].
Predictive biomarker analysis
To investigate the molecular characteristics of the TNBC
and their potential predictive value in prognosis and ther-
apeutic response, tumor specimens for TP53 mutation and
molecular subtype by PAM50 were analyzed (Table 4).
Fig. 1 Patient outcome.
Kaplan–Meier survival curves
on time to treatment failure
(TTF) (a) and OS (b) for all
patients and Kaplan–Meier
survival curves on TTF (c) and
OS (d) by tumor TP53 mutation
status
488 Breast Cancer Res Treat (2013) 137:483–492
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Among the 25 patients enrolled, one withdrew consent and
a specimen was not requested, three were without available
archival tumor specimens, and five had archival tumor
specimens with limited cellularity, and one each had poor
quality DNA and RNA, respectively. Among the 15
patients with sufficient specimens for PAM50 analysis,
there were ten basal-like, one basal/HER2-enriched, two
HER2-enriched, and two luminal B. Among the 15 patients
with sufficient tumors for analysis, eight (53 %) carried
mutations in TP53. In this limited dataset, there was no
significant difference in TTF between the two populations
(Fig. 1c), but a significantly worse OS was observed in
patients with mutations in TP53. The median OS was 5.5
(95 % CI: 2, 11) months and 20.3 (95 % CI: 3, 24) months
in patients with and without TP53 mutation (p = 0.004),
respectively (Fig. 1d).
Fig. 2 Pharmacodynamic effects of UCN-01 on PBMC (a, b) and
tumor tissue (c–h). PBMC were collected at baseline (BL), 24 h post
irinotecan but prior to UCN-01 on day 2 (D2), 24 h post UCN-01 on
day 3 (D3), and on day 8 (D8) prior to the second irinotecan treatment
during cycle 1. PBMC were lysed and analyzed by western blotting
with antibodies specific for total and phosphorylated forms of S6
ribosomal protein (S6), AKT, and GSK3ß with actin as a loading
control. Representative western blots from two patients (4 and 11) are
shown (a). The ratio of pS6 to total S6 protein level was plotted at
each time point (b). Optional serial tumor biopsies were collected
before study drug therapy at baseline (BL), 24 h post irinotecan but
prior to UCN-01 on day 2 (D2), and 24 h post UCN-01 on day 3 (D3)
from 4 patients (1, 4, 6, and 11). Representative immunofluorescent
(IF) staining images on tumors from patient 11 are shown in (c). The
quantitation of the IF analysis on the cH2AX (d), pChk1S296 (e),
phistone H3 (f), cleaved caspase 3 (g), and pS6 (h), for each patient is
shown in the lower panels. CC3 cleaved caspase 3
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Discussion
Irinotecan administered weekly as a single agent has been
shown to induce an overall response rate of 5–23 % in
unselected patients with metastatic breast cancers resistant
to anthracycline and/or taxane [37, 38]. In this study,
women with resistant TNBC had previously received both
an anthracycline and a taxane and had a median of 3
chemotherapy regimens. The overall response rate to iri-
notecan in combination with UCN-01 was 4 % and TTF
was 1.7 months in our study. Given the low response rate
observed, UCN-01, when administered on a day 2 and 23
schedule in combination with weekly irinotecan (days 1, 8,
15, 22), did not appear to potentiate the cytotoxic effects of
irinotecan.
The pharmacodynamics studies on serially collected
PBMC and tumor biopsies revealed limited bioavailability
of UCN-01 to tissue, likely as a result of the high affinity
binding of this agent to the a1-acid glycoprotein (AAG)
[28, 39–41]. Despite the higher dose of UCN-01 on day 2
compared to subsequent doses, the initial suppression of
pS6 in PBMC on day 3 was no longer detected by day 8, a
similar finding from our initial phase I study of this com-
bination [28]. In addition, the inhibitory effect of UCN-01
on tumor tissue Chk1, which was activated by irinotecan in
all tumors on day 2, was inconsistent although pS6 was
inhibited on day 3. These data support the notion that
UCN-01 was not able to achieve the desired Chk1 inhibi-
tion, likely due to the limited tissue bioavailability with the
current dosing and scheduling. Interestingly, patient 11’s
tumor, which had a deletion in TP53 and a reduction in
pChk1 following UCN-01, had a dramatic increase in
apoptosis following UCN-01, indicating inhibition of cell
cycle checkpoint and potentiation of the cytotoxic effects
of irinotecan. As anticipated, enhanced apoptosis was not
observed in the tumor from patient 6, which was wild type
for TP53, although there was also a reduction in pChk1
following UCN-01 in this tumor. Further studies of Chk1
inhibitors with improved pharmacokinetic properties and
selectivity for Chk1 are needed [13].
Analysis of cH2AX, pChk1, and cleaved caspase 3 on
serial biopsies obtained from four patients at baseline and
on day 2 after irinotecan indicated that although irinotecan
induced anticipated DNA damage and activation of
checkpoint pathways, the effect on apoptosis was minimal.
The failure to induce cell death following DNA damage
indicates mechanisms in place in these tumors to counter-
act the apoptotic effect of irinotecan, and these resistance
mechanisms remain to be elucidated. These data highlight
the need for a better understanding of treatment resistance
to chemotherapy for TNBC.
As reported in the literature [42, 43], we observed a
significant heterogeneity in TNBC in this study. Most of
the tumors were basal-like by PAM50 breast cancer
molecular subtyping; other subtypes included HER2-enri-
ched and luminal B. The frequency of each subtype is
consistent with previous reports [43–45]. Despite its small
sample size, this study demonstrates that TP53 mutation is
a robust predictor of worse clinical outcome in patients
with metastatic TNBC. In a single institution small retro-
spective study of 135 patients with early stage breast
cancer, including 32 patients with TNBC treated with
adjuvant anthracycline-based chemotherapy, p53 status
assessed by IHC was strongly predictive of relapse free
survival and OS only in the TNBC cases [46]. Similar
findings were obtained in another retrospective study that
used IHC analysis [47]. Our study provides important
confirmatory evidence that TP53 mutation is a predictor of
worse outcome in the anthracycline and taxane resistant
metastatic TNBC patient population. The significant dif-
ference in outcome indicates a need to stratify patients
based on TP53 status in the design of clinical trials in
patients with metastatic TNBC. Though we were not able
to obtain specimens on all patients, the biomarker analyses
of PBMC, archival tumor, and biopsy specimens that were
obtained have provided important insights into the biology
of TNBC when treated with UCN-01 in combination with
irinotecan.
Conclusions
In this trial, we examined the therapeutic potential of UCN-
01, the first identified Chk1 inhibitor, in combination with
irinotecan, in patients with metastatic TNBC. Although the
clinical activity was unimpressive most likely due to the
pharmacokinetic property of UCN-01, we developed
effective pharmacodynamic markers to evaluate target
inhibition for this class of agents. Our data indicated that
effective Chk1 inhibition could enhance chemotherapy-
induced apoptosis in TP53 mutant tumors. Furthermore, we
demonstrated that TNBC is molecularly heterogeneous and
TP53 mutant TNBC was associated with a particularly
poor survival, indicating a need to stratify patient popula-
tions in clinical trials. These results provide a foundation
for future trials of Chk1 inhibitors in TNBC.
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